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The traveler to, or expatriate residing in, rural areas
of developing countries for prolonged periods is at
greater risk of illness than the short-term traveler.1 This
is a result of increased and more intense exposure to
pathogens and their vectors or reservoirs, poorly devel-
oped infrastructure for water supply and sewerage dis-
posal, limited environmental hygiene, extreme climates,
potentially greater risk-taking behavior, and limited
availability of medical facilities.Risk may be reduced by
appropriate counseling, and vaccination and prophylac-
tic medication based on the best available epidemiolog-
ical data. This paper aims to provide travelers and
practitioners with guidelines for reducing the risk of
acquiring important infectious diseases associated with
long-term travel or placement in rural Africa, a topic that
is generally neglected.2 The diseases discussed were cho-
sen on the basis of their frequency or potential severity
and include yellow fever,malaria, tick-borne infections,
food and waterborne disease, schitosomiasis, rabies, and
tuberculosis.
Yellow Fever
This is the only vaccination required by law for trav-
elers residing or traveling through endemic regions of
West and Central Africa.The risk of exposure is greater
for expatriates residing in endemic rural areas bordering
forests where the disease is enzootic than for short-term
business or vacation travelers who do not venture out of
“concrete capital cities.” High-risk groups include mis-
sionaries, military and agriculture personnel, and eco-
tourists.Vaccination with the attenuated live viral vaccine
(17D) confers protective immunity for at least 10 years.3,4
Generally, individuals with absolute contraindications
must be advised not to enter a yellow fever endemic area.
Although pregnant women in their first trimester should
be advised to delay their trip, vaccination could be con-
sidered for those who insist on residing in a rural endemic
area.5 Vaccination during the first trimester is believed
to pose only a small theoretical risk to the mother and
fetus that may be outweighed by the risk of infection.6
Vaccination may even be considered in individuals
with egg allergy as administration of other egg-cultured
vaccines has been safely administered in people with estab-
lished egg allergies.7,8 However,vaccination in such cases
should be conducted in a health-care setting where
resuscitation facilities are immediately available.
The decision to immunize immunocompromised
travelers should be based on an evaluation of the sever-
ity of immunosuppression and weighed against the risk
of exposure to the virus. As immunization may be less
effective than in immunocompetent persons, measure-
ment of neutralizing antibody response should be con-
sidered following vaccination.9
Ideally,children less than 9 months of age should not
be vaccinated with yellow fever vaccine as they are at
increased risk of developing vaccine-induced encephali-
tis.Although vaccination is contraindicated in infants less
than 4 months of age, it should be considered in older
children when the risk of infection outweighs the risk
of vaccination.6
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In addition, all long-term travelers should be care-
fully briefed on the epidemiology of yellow fever so that
they can practice sensible mosquito avoidance and per-
sonal protection measures. A date for their yellow fever
booster after 10 years should be provided.
Malaria
Nonimmune persons traveling to Plasmodium falci-
parium endemic areas are at high risk for developing life-
threatening illness if they become infected. Studies from
Africa and other malaria-endemic areas indicate that
malaria risk is associated with both the duration and
intensity of exposure.10,11 Holoendemic malaria is pre-
sent in many tropical African countries and particularly
at low altitudes.The importance of compliance with per-
sonal protection against anopheline vector mosquitoes
should form a major part of the pretravel consultation
and be supported with user-friendly reference mater-
ial.12,13 Measures include building dwellings far from mos-
quito breeding sites, mechanical barriers (shoes, socks,
and long trousers, window and door screens, bed nets),
and chemical barriers ( permethrin treatment of cloth-
ing, curtains, and bed nets, space repellents, residual
indoor spraying, and application of effective insect repel-
lents). These measures would also protect the traveler
against other arthropod-borne illnesses including dengue
and filariasis.
Where possible, individuals and corporations should
consult an entomologist who is acquainted with the
breeding and biting behavior of the local vector mos-
quitoes for advice on protective measures, including
appropriate environmental modification. These experts
may also be able to advise on mechanical or chemical
treatment, including larviciding of breeding sites.
Application of residual insecticides to walls should
preferably be done by trained local people using effec-
tive insecticides with low mammalian toxicity. Individ-
uals who undertake spraying themselves should be
carefully instructed on safety precautions and correct
application methods.
Advice on chemoprophylaxis for long-term travel-
ers is fraught with controversy,personal opinion,and non-
science.The reality is that many travelers are loath to take
prolonged preventive medication because of percep-
tions regarding exposure,potential for adverse events, fear
of long term side effects, and ability and willingness to
comply.
Preventive medication is generally recommended ini-
tially but the recommended duration of sustained use is
controversial.Unfortunately, research necessary to guide
this decision has not yet been conducted and there are
no accurate markers of acquired immunity to malaria cur-
rently available.
The chemoprophylactic agents of choice for peo-
ple living in high risk areas are mefloquine or doxycy-
cline, as these have been shown to be most effective.14,15
The combination of atovaquone and proguanil has
recently been licensed by the United States Food and
Drug Administration and it is also available in many
European countries.16 Use of long-term mefloquine
chemoprophylaxis appears safe, although the occurrence
of serious neuropsychiatric adverse events may occur after
a delay.4 The risk of serious adverse events with prolonged
doxycycline use is unknown. The US Armed Forces,
Peace Corps, and Diplomatic Corps (Wolf M, June 2000,
personal communication), and other military personnel
have, however, utilized both doxycycline and meflo-
quine for high-risk individuals for prolonged periods of
time.17,18 Alternatives to long-term chemoprophylaxis
should be discussed. These would include the selective
use of chemoprophylaxis during high-risk periods and
provision of counseling on the use of standby medica-
tion. Travelers should consult credible local medical
authorities who will acquaint them with high-risk peri-
ods when preventive medication should be taken and
serve as a source of medical care should the traveler
become ill.
Standby therapy should be provided for use when
no reliable medical services are readily available. In-
dividuals should also be advised to travel to the nearest
medical facility without delay.Medication used in standby
therapy includes sulphadoxine/pyr imethamine,
artemesinin derivatives, mefloquine or quinine, and the
combination of atovaquone and proguanil. Quinine
should not be used as a standby treatment, if meflo-
quine has been taken as chemoprophylaxis since serious
cardiac adverse events may occur.Quinine can,however,
be utilized for treatment where adequate monitoring facil-
ities are available.
Children under 5 years of age are at increased risk
for developing severe malaria if they become infected
and should preferably not enter a malaria endemic
area.19 Children weighing more than 5 kilograms who
must travel to or reside in a malaria area should utilize
mefloquine chemoprophylaxis, as doxycycline use is
contraindicated because of adverse effects on skeletal and
dental development.
Pregnant women are also at increased risk of severe
complications and should preferably not enter a malaria
area. Those living in a malaria endemic area should use
the combination of chloroquine and proguanil,which is
safe in pregnancy.5 Mefloquine may be considered dur-
ing the first trimester of pregnancy only if the benefit jus-
tifies the potential risk to the fetus, although this risk
appears to be small.20
Although accurate when used in a professional lab-
oratory environment or in the field by trained health
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personnel,21,22 rapid malaria diagnostic kits used by trav-
elers have been found to be unsatisfactory. Travelers
have difficulty in performing and interpreting these
tests.23 Valuable time may be lost if the test is misinter-
preted, and a positive test provides no indication of the
severity of disease. It is critical that all long-term travel-
ers into malaria endemic regions of Africa be counseled
that an acute febrile illness must be regarded as malaria,
and urgent care sought.The traveler should be informed
that a single negative test does not exclude malaria and
that multiple tests may be required so that they will
demand this where necessary.
Malaria is one of very few infectious diseases that
may be life-threatening if not immediately treated and
serves in its own right as an excellent reason for com-
prehensive travel insurance, including emergency evac-
uation. Travel health insurance has been discussed
elsewhere.24
Ticks
Ticks are important vectors of viral, spirochetal, and
rickettsial disease, e.g., African tick bite fever. Both long
and short-term travelers should take precautions against
tick bites by using repellents (skin and clothing). In addi-
tion, individuals should inspect their bodies for ticks.
Important sites include the groin and scalp hairline.
If ticks are found, they should be removed by gen-
tle traction using forceps. Then an antiseptic should be
applied to the wound. Travelers should be educated
about presenting symptoms and the need to consult and
provide their practitioners with a travel history should
they become ill.
Food and Waterborne Diseases
These diseases are an important and frequent
cause of morbidity in travelers. The risk of develop-
ing travelers’ diarrhea may be as high as 40% for short
term travelers into high risk areas of Africa.25 The risk
in the long-term rural travelers may be compounded
by the lack of sanitized water and waterborne sewer-
age. Strategies to prevent illness include vaccination
against water and foodborne fecal-oral infections,
practice of good food and water hygiene, and provi-
sion of standby therapy.
Vaccines indicated for long-term travelers from
developed settings with long-term residence in rural
Africa include those against hepatitis A, poliomyelitis,
and typhoid. All children, except those under the age
of 2 years, should be vaccinated against hepatitis A.
Although improved vaccines against cholera are becom-
ing available, the primary protection against cholera
remains careful food and water hygiene. Water should
ideally be filtered, boiled for an adequate period of time
allowing for altitude, and then chlorinated. Alternative
strategies include the addition of iodine,or use of iodine
resin filters. Traveling with children has been discussed
elsewhere.26
Milk may harbor pathogens including Brucella spp,
enteric organisms, and Mycobacterium bovis. Where pas-
teurized milk is not available, milk should be boiled
prior to use. Pasteurized powdered milk or milk con-
centrate may also be used. Unpasturized cheeses should
be avoided.
Standby therapy with a quinolone antimicrobial
should be taken if an individual develops dysentery or
severe travelers’ diarrhea. Quinolone antimicrobials are
also indicated in children with life-threatening diarrhea.
Although quinolones are not registered for use in chil-
dren, when they have been used, joint symptoms were
rare and appeared to be reversible.27 Antimicrobial ther-
apy should be combined with sufficient quantities of rehy-
dration fluid to compensate for fluid loss.
Returning travelers should be asked about gastroin-
testinal symptoms and, if these are present, they deserve
further investigation. A screening stool examination to
exclude parasitic infections should be considered.
Schistosomiasis (Bilharziasis)
Schistosomiasis is another important health risk to
the long-term rural traveler as it may cause chronic gas-
trointestinal (Schistosoma mansoni) and genitourinary
(Schistosoma haematobium) disease. It is found in an area
between latitudes 36 degrees North and 34 degrees
South in Africa, where freshwater temperatures average
25 to 30°C.28
Apart from avoidance advice (keeping out of unpro-
tected and untreated water bodies or using protective
boots when fording streams or fishing), screening serol-
ogy prior to traveling and upon return should be offered.
Individuals who seroconvert should be investigated and
treated.Alternatively, stool and urine examination for par-
asites could be performed as a routine procedure on
long-term travelers returning from rural Africa.
Zoonotic Diseases
Zoonotic exposures that may present a hazard to the
long-term traveler in rural Africa include bovine tuber-
culosis, leptospirosis, anthrax,plague,and even certain viral
hemorrhagic fevers. As leptospirosis is transmitted by
rodents, rodent control measures should be instituted both
at home and in the work place.
Rabies is certainly the most important and deadly
zoonotic adversary that may be encountered. In rural
Africa, transmission is usually by the bite of infected ani-
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mals. The long-term rural traveler is at risk of exposure
to infected animals and pre-exposure vaccination is indi-
cated. This is particularly important in countries where
rabies immune globulin (RIG) and vaccine may not be
available and health workers may not be acquainted with
the correct management protocols. Pre-exposure vacci-
nation eliminates the need for RIG and reduces the num-
ber of vaccine doses required following exposure. It may
also provide some protection until the necessary booster
doses of vaccine can be sourced.Potential exposure to rabies
is another essential justification for adequate emergency
travel insurance. Travelers should be firmly cautioned
against approaching animals or keeping exotic pets.
Sexually Transmitted Infections
Travelers may be a source of sexually transmitted
infections (STIs) to the host population or may acquire
a STI during travel. The long-term single traveler may
be at higher risk of infection.
Travelers should be counseled regarding the risk and
prevention of STIs particularly as HIV and hepatitis B
prevalence is high in rural subSaharan Africa.Female trav-
elers may be at risk for rape and thus informed that pro-
phylactic antiretroviral therapy is available. Standby
antiretroviral therapy should be considered for people trav-
eling to areas where health care facilities are sparse.
Hepatitis B vaccination should be offered to all travel-
ers, including individuals practicing safe sex, as the virus
may also be transmitted though blood or poorly steril-
ized instruments.
Other Important Infectious Diseases
Travelers are at risk of contracting tuberculosis while
traveling and at their destination, particularly if they
have close contact with the local population in confined
areas.29,30 In US Peace Corps volunteers who stayed in
developing countries, tuberculin conversion occurred at
rates of greater than 3.5 per 100 volunteer years in two
African countries and one Asian country. The rates of
documented skin test conversion per 100 volunteer years
were 0.5 for the African region, 0.6 for the East/Cen-
tral Europe and Mediterranean region, and 0.7 for the
Asia Pacific region.31
Bacille Calmette-Guerin (BCG) vaccination is usu-
ally restricted to young children,where its benefit against
severe disease is unequivocal. Cure is possible when
individuals with suggestive symptoms present early and
are adequately assessed with suitable microbiological
and radiological diagnostic services.32
Active disease should be excluded in those exposed
to tuberculosis or who are symptomatic. Periodic skin
testing and administration of chemoprophylaxis to patients
with skin test conversion is advocated by some authors,
although this justifiably remains a controversial approach.33
Vaccination with BCG may also result in false pos-
itive reactions to the purified protein derivative (PPD)
skin tests.
Long-term travelers should be screened with PPD
prior to departure and 10 to 12 weeks after return, this
period being necessary to include incubating disease.
They should also be educated about the symptoms of
disease and encouraged to present early should they
become ill.
Meningococcal Meningitis
This is a rapidly progressive and potentially fatal infec-
tion that may be encountered in Africa, particularly
West Africa. Meningococcal vaccination is particularly
important for travelers who will be in close contact
with the local population during epidemics and for
those people living in the meningococcal meningitis
belt of subSaharan Africa.6
Medical Examination Prior to Travel
All long-term travelers should undergo an exten-
sive medical and dental examination to exclude under-
lying disease, prior to their departure. Dental problems
may occur at any time and dental treatment may not be
readily available. Dental health and travelers is discussed
elsewhere.34
The pretravel consultation should also be used as an
opportunity for catching up on missed immunization
opportunities.All travelers who have not been boostered
with tetanus vaccine in the previous 10 years should, for
example, be immunized.
As medical facilities in many developing countries
may be suboptimal and care difficult to access, subclin-
ical conditions should be excluded and treated prior to
departure.Travelers should also be equipped with a first
aid kit, as certain simple remedies may not be available
in developing countries.Provision of sterile syringes and
catheters should be considered for high-risk travelers,
with the appropriate medical authorization.
Travelers should be followed up on their return or
at suitable intervals. Laboratory tests conducted may
include blood tests for liver and kidney function,glucose
determination, and examination of urine and stool for
parasites.
Increasing numbers of employees from developed
countries are being stationed in rural Africa and are thus
being exposed to infectious diseases as an occupational
hazard. Occupational health personnel are therefore an
important target group for information on exposures of
expatriates to infectious diseases in Africa,particularly in
terms of health and safety legislation.35
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Conclusions
The long-term traveler to Africa may have a
higher risk profile and require expert guidance. All
potential exposures should be explored and repeated
counseling sessions may be required before travelers
embark on their journey, as little expert advice, drugs,
or suitable equipment may be available at their desti-
nation. Where possible on-site contact and monitor-
ing via electronic or telephone communication should
be encouraged.
The advice in this paper is extrapolated from the lim-
ited number of studies conducted amongst long-term
travelers. Further research into appropriate risk man-
agement is needed in terms of infectious diseases and other
important aspects of their welfare, including their psy-
chological and physical well being.
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